Laëtitia Largeaud

652 total citations
34 papers, 211 citations indexed

About

Laëtitia Largeaud is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Laëtitia Largeaud has authored 34 papers receiving a total of 211 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 11 papers in Molecular Biology and 11 papers in Genetics. Recurrent topics in Laëtitia Largeaud's work include Acute Myeloid Leukemia Research (19 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Laëtitia Largeaud is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Laëtitia Largeaud collaborates with scholars based in France, Austria and Germany. Laëtitia Largeaud's co-authors include Jean‐Baptiste Rieu, Isabelle Luquet, Christian Récher, Éric Delabesse, Sarah Bertoli, Véronique Mansat‐De Mas, Suzanne Tavitian, François Vergez, Pierre Bories and Audrey Sarry and has published in prestigious journals such as The Journal of Experimental Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Laëtitia Largeaud

31 papers receiving 209 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laëtitia Largeaud France 10 108 76 68 43 30 34 211
Ya-Ching Hsieh United Kingdom 9 70 0.6× 105 1.4× 41 0.6× 76 1.8× 25 0.8× 12 268
Afaf E.G. Osman United States 7 121 1.1× 93 1.2× 65 1.0× 15 0.3× 24 0.8× 20 201
Alexander Coltoff United States 8 84 0.8× 44 0.6× 66 1.0× 20 0.5× 27 0.9× 25 167
Vassilios Aslanis United States 9 61 0.6× 67 0.9× 34 0.5× 42 1.0× 6 0.2× 18 210
Metis Hasipek United States 9 102 0.9× 188 2.5× 23 0.3× 58 1.3× 6 0.2× 26 272
Fabienne Lucas United States 8 77 0.7× 68 0.9× 68 1.0× 60 1.4× 6 0.2× 22 192
Federica Portale Italy 6 23 0.2× 50 0.7× 34 0.5× 71 1.7× 10 0.3× 7 180
R. Hehlmann Germany 8 212 2.0× 83 1.1× 194 2.9× 14 0.3× 111 3.7× 20 308
Claudia Canofari Italy 7 33 0.3× 51 0.7× 12 0.2× 65 1.5× 152 5.1× 11 257
Louis Williams United States 9 110 1.0× 84 1.1× 22 0.3× 29 0.7× 3 0.1× 44 185

Countries citing papers authored by Laëtitia Largeaud

Since Specialization
Citations

This map shows the geographic impact of Laëtitia Largeaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laëtitia Largeaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laëtitia Largeaud more than expected).

Fields of papers citing papers by Laëtitia Largeaud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laëtitia Largeaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laëtitia Largeaud. The network helps show where Laëtitia Largeaud may publish in the future.

Co-authorship network of co-authors of Laëtitia Largeaud

This figure shows the co-authorship network connecting the top 25 collaborators of Laëtitia Largeaud. A scholar is included among the top collaborators of Laëtitia Largeaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laëtitia Largeaud. Laëtitia Largeaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Largeaud, Laëtitia, Naïs Prade, Christine Didier, et al.. (2025). GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome. Blood Cancer Journal. 15(1). 7–7. 2 indexed citations
2.
Largeaud, Laëtitia, Juliette Lambert, Philippe Rousselot, et al.. (2024). The AXL inhibitor bemcentinib overcomes microenvironment‐mediated resistance to pioglitazone in acute myeloid leukemia. FEBS Journal. 292(1). 115–128. 5 indexed citations
3.
Cadot, Sarah, S. Ken, Loı̈c Dupré, et al.. (2024). New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling. PLoS Medicine. 21(7). e1004430–e1004430. 1 indexed citations
4.
Leroy, Harmony, Emilie Bérard, Isabelle Luquet, et al.. (2024). Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy. Cancer Medicine. 13(3). e7003–e7003. 1 indexed citations
5.
Guermouche, Hélène, Pierre Hirsch, Frédéric Picou, et al.. (2023). Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals. Clinical Immunology. 255. 109730–109730. 11 indexed citations
6.
Mouchel, Pierre‐Luc, Emilie Bérard, Suzanne Tavitian, et al.. (2023). Vitamin C and D supplementation in acute myeloid leukemia. Blood Advances. 7(22). 6886–6897. 10 indexed citations
7.
Largeaud, Laëtitia, Naïs Prade, Isabelle Luquet, et al.. (2023). Stem cell–like reprogramming is required for leukemia-initiating activity in B-ALL. The Journal of Experimental Medicine. 221(1). 2 indexed citations
8.
Rieu, Jean‐Baptiste, et al.. (2022). Unexplained iron overload with haemolytic anaemia should prompt looking for morphological changes in erythroid precursors. British Journal of Haematology. 197(2). 132–132. 1 indexed citations
9.
Bertoli, Sarah, Laëtitia Largeaud, Jean‐Baptiste Rieu, et al.. (2022). Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia. Clinical Cancer Research. 29(1). 134–142. 11 indexed citations
10.
Mas, Véronique Mansat‐De, et al.. (2021). Chronic Myeloid Leukaemia with isolated massive thrombocytosis and BCR‐ABL1 detection failure using RT‐MLPA (positive RT‐qPCR). SHILAP Revista de lepidopterología. 2(3). 655–656. 1 indexed citations
11.
Rieu, Jean‐Baptiste, et al.. (2021). Characteristic vacuolisation of granulocytic and erythroid precursors associated with VEXAS syndrome. British Journal of Haematology. 194(1). 8–8. 14 indexed citations
12.
Singh, Preeti, Anastasia Resteu, Aneta Mikulášová, et al.. (2021). GATA2 deficiency phenotype associated with tandem duplication of GATA2 and overexpression of GATA2-AS1. Blood Advances. 5(24). 5631–5635. 5 indexed citations
13.
Duployez, Nicolas, Matthieu Duchmann, Laëtitia Largeaud, et al.. (2021). Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study. Blood. 138(Supplement 1). 612–612.
14.
Tavitian, Suzanne, Sarah Bertoli, Françoise Huguet, et al.. (2020). Dactinomycin in acute myeloid leukemia with NPM1 mutations. European Journal Of Haematology. 105(3). 302–307. 9 indexed citations
15.
Rieu, Jean‐Baptiste, Jill Corre, Suzanne Tavitian, et al.. (2020). A case of cup‐like blasts associated with B‐lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations. SHILAP Revista de lepidopterología. 1(2). 589–592. 1 indexed citations
16.
Rieu, Jean‐Baptiste, Aurore Perrot, François Vergez, Laëtitia Largeaud, & Jill Corre. (2020). When dystrophic plasma cells do not recognize themselves in the mirror. SHILAP Revista de lepidopterología. 1(2). 408–408. 1 indexed citations
17.
Vergez, François, Marie-Laure Nicolau-Travers, Sarah Bertoli, et al.. (2020). CD34+CD38−CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. Cancers. 12(5). 1174–1174. 11 indexed citations
18.
Dumas, Pierre‐Yves, Sarah Bertoli, Emilie Bérard, et al.. (2020). Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. Cancers. 12(8). 2044–2044. 5 indexed citations
19.
Cadot, Sarah, Carine Valle, Marie Tosolini, et al.. (2020). Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse. Biomarker Research. 8(1). 72–72. 20 indexed citations
20.
Largeaud, Laëtitia, Emilie Bérard, Sarah Bertoli, et al.. (2019). Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. Leukemia Research. 81. 82–87. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ya-Ching Hsieh Breakdown of academic impact, for papers by Afaf E.G. Osman Breakdown of academic impact, for papers by Alexander Coltoff Breakdown of academic impact, for papers by Vassilios Aslanis Breakdown of academic impact, for papers by Metis Hasipek Breakdown of academic impact, for papers by Fabienne Lucas Breakdown of academic impact, for papers by Federica Portale Breakdown of academic impact, for papers by R. Hehlmann Breakdown of academic impact, for papers by Claudia Canofari Breakdown of academic impact, for papers by Louis Williams
Rankless by CCL
2026